---
document_datetime: 2023-09-21 18:30:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_en.pdf
document_name: prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3891947
conversion_datetime: 2025-12-18 10:41:14.910962
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## EU Number

EU/1/08/478/001

Pharmaceutical

Form

Route of

Administration

Intramuscular use

Packaging suspension (H5N1):

vial (glass)

emulsion (adjuvant):

vial (glass)

Content

2.5 ml (suspension)

2.5 ml (emulsion)

Invented name Strength Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmith Kline Biologicals 3.75 Âµg HA Suspension and Emulsion for emulsion for injection Medicinal product no longer authorised

Package size

50 vials (suspension)

2 x 25 vials (emulsion)